Related Experiment Video
Updated: Aug 23, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
Published on: July 7, 2016
Cardiovascular pharmacotherapeutic considerations during pregnancy and lactation
Shadi A Qasqas1, Camille McPherson, William H Frishman
1Departments of Medicine, Washington University School of Medicine/Barnes-Jewish Hospital, St. Louis, Missouri, USA.
Abstract:
Cardiovascular drugs are often used in pregnancy for the treatment of maternal and fetal conditions. Mothers could also require continued postpartum drug therapy. Most cardiovascular drugs taken by pregnant women can cross the placenta and therefore expose the developing embryo and fetus to their pharmacologic and teratogenic effects. These effects are influenced by the intrinsic pharmacokinetic properties of a given drug as well as by the complex physiological changes occurring during pregnancy. Many drugs are also transferred into human milk and therefore can potentially have adverse effects on the nursing infant. This 2-part article summarizes some of the available literature concerning the risks and benefits of using various cardiovascular drugs and drug classes during pregnancy and lactation. Included in the discussion are cardiac glycosides, antiarrhythmic drugs, drugs used to treat both acute and chronic hypertension, cholesterol-lowering agents, anticoagulants, thrombolytics, and antiplatelet drugs.
Related Concept Videos
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Cardiovascular Drugs: Classification based on Therapeutic Indications
Cardiopulmonary Resuscitation IV: Pharmacological Management
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
Factors Affecting Drug Response: Overview
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...